5,957
Views
51
CrossRef citations to date
0
Altmetric
Review

Cannabinoid interactions with ion channels and receptors

Pages 162-167 | Received 27 Mar 2019, Accepted 30 Apr 2019, Published online: 15 May 2019

References

  • Serpell M, Ratcliffe S, Hovorka J, et al. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999–1012.
  • Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Can Med Assoc J. 2010;182(14):E694–E701.
  • Wilsey B, Marcotte T, Deutsch R, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136–148.
  • Casey SL, Atwal N, Vaughan CW. Cannabis constituent synergy in a mouse neuropathic pain model. Pain. 2017;158(12):2452–2460.
  • Kaplan JS, Stella N, Catterall WA, et al. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci. 2017;114(42):11229–11234.
  • Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278.
  • Ceprián M, Jiménez-Sánchez L, Vargas C, et al. Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke. Neuropharmacology. 2017;116:151–159.
  • Ribeiro A, Almeida VI, Costola-de-Souza C, et al. Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacol Immunotoxicol. 2015;37(1):35–41.
  • Shevyrin V, Melkozerov V, Endres GW, et al. On a New Cannabinoid Classification System: a Sight On The Illegal Market Of Novel Psychoactive Substances. Cannabis Cannabinoid Res. 2016;1(1):186–194.
  • Komorowski J, Stepień H. [The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans]. Postepy Hig Med Dosw (Online). 2007;61:99–105. [cited 2018 Nov 26]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17369778
  • Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215.
  • Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129–180.
  • Ryan D, Drysdale AJ, Lafourcade C, et al. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci. 2009;29(7):2053–2063.
  • Duan Y, Liao C, Jain S, et al. The cannabinoid receptor agonist CP-55,940 and ethyl arachidonate interfere with [3H]batrachotoxinin A 20 α-benzoate binding to sodium channels and inhibit sodium channel function. Comp Biochem Physiol Part C Toxicol Pharmacol. 2008;148(3):244–249.
  • Okada Y, Imendra KG, Miyazaki T, et al. Biophysical properties of voltage-gated Na+ channels in frog parathyroid cells and their modulation by cannabinoids. J Exp Biol. 2005;208(24):4747–4756.
  • Poling JS, Rogawski MA, Salem N, et al. Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels. Neuropharmacology. 1996;35(7):983–991. [cited 2018 Sept 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8938728.
  • Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131–1141.
  • Rimmerman N, Ben-Hail D, Porat Z, et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis. 2013;4(12):e949–e949.
  • Soderstrom K, Soliman E, Van Dross R. Cannabinoids modulate neuronal activity and cancer by CB1 and CB2 receptor-independent mechanisms. Front Pharmacol. 2017;8:720.
  • Ghovanloo M-R, Shuart NG, Mezeyova J, et al. Inhibitory effects of cannabidiol on voltage-dependent sodium currents Running title: CBD Inhibition of Nav Currents. doi:10.1074/jbc.RA118.004929
  • Thomas A, Baillie GL, Phillips AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613–623.
  • Ahern CA, Payandeh J, Bosmans F, et al. The hitchhiker’s guide to the voltage-gated sodium channel galaxy. J Gen Physiol. 2016;147(1):1–24.
  • Oz M, Yang K-H, Dinc M, et al. The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed xenopus oocytes. J Pharmacol Exp Ther. 2007;323(2):547–554.
  • Hejazi N, Zhou C, Oz M, et al. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol. 2006;69(3):991–997.
  • Ahrens J, Demir R, Leuwer M, et al. The nonpsychotropic cannabinoid cannabidiol modulates and directly activates Alpha-1 and Alpha-1-Beta glycine receptor function. Pharmacology. 2009;83(4):217–222.
  • De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479–1494.
  • Ross HR, Napier I, Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem. 2008;283(23):16124–16134.
  • Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A. 2006;103(20):7895–7900.
  • Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2009;152(7):1092–1101.
  • Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res. 2005;30(8):1037–1043.
  • De Petrocellis L, Vellani V, Schiano-Moriello A, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of Ankyrin Type-1 and melastatin Type-8. J Pharmacol Exp Ther. 2008;325(3):1007–1015.
  • Andersen OS, Nielsen C, Maer AM, et al. [10] Ion channels as tools to monitor lipid bilayer-membrane protein interactions: Gramicidin channels as molecular force transducers. Methods Enzymol. 1999;294:208–224.
  • Lundbæk JA, Birn P, Girshman J, et al. Membrane stiffness and channel function. Biochemistry. 1996;35(12):3825–3830.
  • Koeppe RE, Anderson OS. Engineering the Gramicidin channel. Annu Rev Biophys Biomol Struct. 1996;25(1):231–258.
  • Teng Q, Koeppe RE, Scarlata SF. Effect of salt and membrane fluidity on fluorophore motions of a gramicidin C derivative. Biochemistry. 1991;30(32):7984–7990. [cited 2018 Nov 21]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1714298.
  • Sychev SV, Sukhanov SV, Telezhinskaya IN, et al. Effective lipid-detergent system for study of membrane active peptides in fluid liposomes. J Pept Sci. 2016;22(2):98–105.
  • Lundbaek JA, Birn P, Hansen AJ, et al. Regulation of sodium channel function by bilayer elasticity: the importance of hydrophobic coupling. Effects of Micelle-forming amphiphiles and cholesterol. J Gen Physiol. 2004;123(5):599–621.